In this webinar, you will learn how Pelago Bioscience can support the early stages of hit identification and validation in a high throughput manner with CETSA^® Navigate HT and how CETSA^® Explore provides a proteome-wide analysis of the effects of the PROTACs^® to assess their selectivity and with potential to elucidate the MoA.

Targeted protein degradation using PROTACs^® has become an important therapeutic strategy that has led to significant investments in the pharmaceutical industry. The modality holds considerable promise and a growing appreciation of the utility of PROTACs^® as chemical probes for target identification and validation. As with other modalities, assuring the efficacy from the early stages of drug discovery is essential to prevent failure at later stages of clinical development.

Pelago Bioscience can provide an integrated solution for your protein degrader program from hit identification to mode of action confirmation. Leveraging on our patented Cellular Thermal Shift Assay (CETSA^®), Pelago Bioscience can support the early stages of hit identification and validation in a high throughput manner with CETSA^® Navigate HT. Applying the same AlphaLISA^® immunoassay used in CETSA^® Navigate HT, we can also effectively monitor protein degradation in function of time and/or concentration of the PROTAC^®, validating its activity. Finally, for a full characterization of your molecules, CETSA^® Explore provides a proteome-wide analysis of the effects of the PROTAC^® to assess its selectivity and with potential to elucidate the MoA.